Aimee E.DeFilippo

Partner

Washington + 1.202.879.7631

Connect:

Share

Aimee DeFilippo has more than 15 years of experience practicing antitrust law, focusing on mergers and acquisitions, counseling, compliance, and nonmerger investigations. She has represented clients before the U.S. Department of Justice, Federal Trade Commission, and state attorneys general and has experience across numerous industries including health care, pharmaceuticals, power, consumer products, agriculture, airlines, communications, and more. Aimee has worked to secure clearances in numerous complex transactions and has steered clients through high-profile government investigations. She also regularly advises clients on antitrust issues involving competitor collaborations, distribution and pricing arrangements, and information sharing. Representative clients include General Electric, Procter & Gamble, Eastman Chemical, Cleveland Clinic, and Yale New Haven Health System.

In addition, Aimee gained substantial experience practicing as an in-house lawyer while on a yearlong secondment with the competition law group of General Electric, where she worked on a wide variety of transactional, counseling, and compliance matters across the globe. She also worked in the legal department of a major U.S. corporation throughout her time in law school.

Aimee recently served a two-year term as chair of the Antitrust Practice Group of the American Health Lawyers Association, and she is also a member of the ABA's Section of Antitrust Law. She has written extensively for both organizations and has published articles in CPI Antitrust Chronicle, Bloomberg BNA, The Antitrust Source, The Threshold, and others. Aimee is also a frequent speaker on antitrust issues, having appeared as a panelist in numerous ABA and AHLA webinars and in-person programs. She also serves on the Bloomberg Law Health Care Practice Innovation Board.

Experience

  • Eastman Chemical Company sells Texas City operations to INEOS Acetyls for $490 millionJones Day advised Eastman Chemical Company (NYSE: EMN) on the sale of its Texas City operations to INEOS Acetyls, a global manufacturer and supplier of acetic acid and related chemicals owned by the INEOS Group for approximately $490 million.
  • Labcorp completes spin-off of FortreaJones Day represented Labcorp (NYSE: LH), a leading global life sciences company, in the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations around the world.
  • Valmet completes statutory merger with NelesJones Day served as global merger control and foreign direct investment counsel to Valmet Oyj (excluding Finland) in its statutory merger with Neles Corporation.
  • Sutter Health wins complete defense verdict in landmark antitrust class actionJones Day won a complete defense jury verdict for Sutter Health in a landmark antitrust class action seeking $1.2 billion in treble damages.
  • Procter & Gamble Company acquires TULA LifeJones Day advised The Procter & Gamble Company in its acquisition of TULA Life, Inc. from L Catterton Partners and L Catterton Europe SAS.
  • Eaton sells hydraulics business to DanfossJones Day advised Eaton Corporation as antitrust counsel in the sale of its hydraulics business to Danfoss Power Solutions for US$3.3 billion.
  • Eaton sells lighting business to SignifyJones Day represented Eaton Corporation as antitrust counsel in the sale of its Cooper Lighting business to Signify N.V. (formerly known as Philips Lighting) for $1.4 billion.
  • Life science company reviews antitrust aspects of strategic allianceJones Day is providing antitrust counsel to a life science company in relation to the establishment of a strategic alliance.
  • GE sells Intelligent Platforms business to EmersonJones Day served as antitrust counsel to General Electric Company in the sale of Intelligent Platforms, a division of General Electric, to Emerson Electric Co.
  • GE Healthcare collaborates with Preventice Solutions Group to develop ambulatory cardiac arrhythmia monitoring suiteJones Day advised GE Healthcare in its collaboration with Preventice Solutions Group to develop an ambulatory cardiac arrhythmia monitoring suite for diagnostic purposes outside of hospitals or clinics.
  • Baker Hughes sells natural gas solutions business to First Reserve and Pietro FiorentiniJones Day advised Baker Hughes, a GE company (BHGE), in the sale of its global Natural Gas Solutions (NGS) business to two separate buyers, First Reserve and Pietro Fiorentini.
  • GE sells GE Industrial Solutions to ABB for $2.6 billionJones Day served as antitrust counsel to General Electric Company in the $2.6 billion sale of GE Industrial Solutions to ABB.
  • GE Healthcare and Roche enter partnership to develop integrated digital diagnostics platformJones Day advised GE Healthcare in its strategic partnership with Roche to develop an integrated digital diagnostics platform relating to oncology and critical care treatment.
  • GE sells GE Water & Process Technologies to Suez for $3.4 billionJones Day served as antitrust counsel to General Electric Company in the €3.2 billion ($3.4 billion) sale of GE Water & Process Technologies to Suez and Caisse de dépôt et placement du Québec.
  • Centura Health forms population health joint venture with DaVita HealthCare PartnersJones Day advised Centura Health Corporation in connection with the development and negotiation of a joint venture arrangement with DaVita HealthCare Partners through which the parties intend to provide population health management services supporting a clinically integrated network of providers serving patients throughout the State of Colorado and Western Kansas.
  • The Carlyle Group sells Vogue International to Johnson & Johnson for $3.3 billionJones Day represented The Carlyle Group as antitrust counsel in the sale of its salon-heritage hair care and personal care products business, Vogue International, to Johnson & Johnson Consumer Inc. for $3.3 billion.
  • Eastman Chemical acquires Commonwealth Laminating & CoatingJones Day advised Eastman Chemical Company in its acquisition of Commonwealth Laminating & Coating, Inc., an independent manufacturer and global marketer and distributor of window films and specialty films for automotive, architectural, and protective applications.
  • Procter & Gamble sells global (excluding most of Europe) pet care business to Mars for $2.9 billionJones Day advised The Procter & Gamble Company in the $2.9 billion sale of its global (excluding most of Europe) pet care business, including its IAMS®, EUKANUBA®, and NATURA® brands, to Mars, Inc.
  • Aventis Pharmaceuticals successfully defends against monopolization claims based on fraud on the Patent Office theoryJones Day resolved class action claims that Aventis Pharmaceuticals, the exclusive licensee of patents covering DDAVP (a treatment for certain water metabolism disorders), knew that the licensor obtained those patents by fraud before the Patent and Trademark Office.
  • American Airlines merges with US Airways in $11 billion dealJones Day represented American Airlines in the antitrust investigation and federal court challenge to its $11 billion merger with US Airways, which closed after the Department of Justice and State attorneys general agreed to settle their lawsuit that sought to block the deal.
    • View All

    March 2024 Alert

    Federal Agencies Launch Joint Inquiry Into Private Investment in Health Care

    February 2024 Alert

    UK CMA Continues Focus on Groceries with Market Study into Baby Formula

    July 2023 White Paper

    DOJ/FTC Propose Massive Changes to HSR Premerger Filings: What You Need to Know

    July/August 2022 External Publications

    U.S. Antitrust Agencies Take Aim at Private Equity, The M&A Lawyer

    October 2021 External Publications

    What a Difference a Year Makes: FTC Withdraws Vertical Merger Guidelines, The M&A Lawyer, Vol. 25, Issue 9

    October 2021 White Paper

    Executive Order on Promoting Competition in the American Economy: A Focus on Patent and Drug Law to Reduce Health Care Spending

    March 2021 External Publications

    Proposed Antitrust Reform Legislation: Sea Change or Nothing to See?, The M&A Lawyer, Vol. 25, Issue 3

    January 2021 Commentary

    New Law Eliminates 75-Year-Old Antitrust Exemption for "Business of Health Insurance"

    September 2020 External Publications

    Anatomy of a Merger: A Practical Guide to Antitrust M&A Reviews for the Uninitiated, The M&A Lawyer, Vol. 24, Issue 8

    July 2019 Alert

    Antitrust Alert: Eighth Circuit Upholds Injunction Against Physician Group Acquisition
    View All

    Additional Publications

    • December 2019
      Contributing Author, ABA The Antitrust Compliance Handbook: A Practitioner's Guide
    • September 2018
      Health Care Networks and Managed Care: Antitrust Aspects of Integration and Exclusion, Bloomberg Law / BNA Health Law & Business Series Portfolio
    • June 9, 2016
      FTC Provides Updated Health Care Enforcement and Policy Resources, Bloomberg BNA Health Law Reporter
    • July 11, 2013
      Timely Use of Antitrust Counsel in Hospital Merger Cases, Bloomberg BNA Health Law Reporter
    • April 2013
      Getting The Tough Deal Done: The Roles of The General Counsel and Outside Antitrust Counsel, CPI Antitrust Chronicle
    • August 2010
      Evaluating Federal and State Antitrust Reviews of Health Insurance Mergers, coeditor, American Health Lawyers Association
    • April 2010
      Contributor, Federal Antitrust Guidelines for Licensing of Intellectual Property (ABA 3rd ed.)
    • February 2010
      Contributor, Antitrust Health Care Handbook (ABA 4th ed.)
    • 2007- present
      Draft numerous Antitrust Alerts for American Health Lawyers Association
    • December 2009
      Authorized Generics: FTC Releases Interim Report, American Health Lawyers Ass'n Life Sciences newsletter, Vol. 3, Issue 3
    • Fall 2007
      Summary of ABA Brown Bag Program on Implications for Merger Analysis from the Evanston Decision, The Threshold, Vol. III, No. 1
    • September 2007
      New Life for Hospital Merger Cases: FTC Ruling Against Evanston Northwestern's Merger with Highland Park, American Health Lawyers Association

    Speaking Engagements

    • September 7, 2023
      Hot off the Press: New Merger Guidelines Proposed, American Health Law Association
    • March 29, 2023
      Cultivating an Ethical Mindset, ABA Section of Antitrust Law Spring Meeting
    • September 27, 2022
      Merger Investigations: Practical Advice in Times of Change, ABA Section of Antitrust Law Teleconference
    • June 28-29, 2022
      Antitrust and Competition Issues in the Pharmaceutical Industry, American Health Lawyers Association Annual Meeting
    • November 29, 2021
      ABA Antitrust Section Corporate Counseling Committee Monthly Update
    • May 19, 2021
      Health Care Antitrust: Meeting the Challenge, panelist, American Health Lawyers Association
    • November 19, 2020
      Recent Developments in Health Care and Pharmaceutical Antitrust, ABA Section of Antitrust Law Teleconference
    • May 1, 2019
      Antitrust Considerations in Negotiating and Preparing for a Merger or Joint Venture, American Health Lawyers Association Health Care Transactions Conference
    • April 2019
      The Capitol Forum Thought Leaders Series
    • December 10, 2018
      Effective Strategies for Dealing with the Antitrust Enforcement Agencies, ABA Health Law Summit
    • June 25, 2018
      Exclusionary Practices in Healthcare and Pharmaceuticals, American Health Lawyers Association Annual Meeting
    • May 10-11, 2018
      No More Flying Under the Radar: Antitrust Scrutiny of Physician Practice Acquisitions, panelist, American Health Lawyers Association Health Care Transactions Conference
    • May 1, 2018
      Jones Day's Media Labor & Employment Law Roundtable
    • May 1, 2018
      Developing L&E Topics: Joint/Single Employer, No-Hire/No-Poaching Agreements, and Other Topics, Jones Day Media Labor & Employment Roundtable
    • October 10, 2017
      Development of a Voluntary Standard, panelist, ASTM ICPHSO Voluntary Standards Workshop
    • May 25, 2017
      Health Care Antitrust Developments, Louisiana State Bar Association Healthcare Law 2017 seminar
    • June 14, 2016
      State Action and Other Immunities and Exemptions, moderator, American Health Lawyers Association
    • May 16, 2016
      Building Your Brand: How to Do It and Why It Is Important, panelist, American Health Lawyers Association
    • February 20, 2014
      The ABC's of Antitrust in Health Care Webinar Series, Part V: Monopolization, panelist, American Health Lawyers Association
    • October 21, 2013
      REMS Restrictions and Generic Entry: What Role for Antitrust?, panelist, ABA Section of Antitrust Law program
    • October 5, 2012
      Developing a Healthcare Antitrust Practice, panelist, American Health Lawyers Association
    • January 12, 2012
      Healthcare Antitrust Bootcamp Webinar Series, Part V: Monopolization, panelist, American Health Lawyers Association
    • September 21, 2010
      Healthcare Merger Enforcement Under the Obama Administration’s Revised Merger Guidelines, panelist, American Health Lawyers Association
    • October 21, 2008
      Why Antitrust?, panelist, ABA Section of Antitrust Law program

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.